Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Encompass Health (EHC) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Encompass Health is a member of the Medical sector. This group includes 1000 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Encompass Health is currently sporting a Zacks Rank of #2 (Buy). Over the past 90 days, the Zacks Consensus Estimate for EHC's full-year earnings has moved 0.9% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger. Based on the latest available data, EHC has gained about 4.1% so far this year. In comparison, Medical companies have returned an average of -7.4%. This means that Encompass Health is outperforming the sector as a whole this year. Heron Therapeutics (HRTX) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 26.1%. For Heron Therapeutics, the consensus EPS estimate for the current year has increased 100% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy). To break things down more, Encompass Health belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 17 individual companies and currently sits at #19 in the Zacks Industry Rank. On average, this group has lost an average of 5.9% so far this year, meaning that EHC is performing better in terms of year-to-date returns. In contrast, Heron Therapeutics falls under the Medical - Drugs industry. Currently, this industry has 162 stocks and is ranked #58. Since the beginning of the year, the industry has moved -7.4%. Encompass Health and Heron Therapeutics could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks. Story Continues Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Encompass Health Corporation (EHC):Free Stock Analysis Report Heron Therapeutics, Inc. (HRTX):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Are Medical Stocks Lagging Encompass Health (EHC) This Year?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...